Comparative Pharmacology
Head-to-head clinical analysis: CORPHEDRA versus PROMETHAZINE W DEXTROMETHORPHAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORPHEDRA versus PROMETHAZINE W DEXTROMETHORPHAN.
CORPHEDRA vs PROMETHAZINE W/ DEXTROMETHORPHAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CorphEdra is a synthetic glucocorticoid that binds to the glucocorticoid receptor (GR), leading to transcriptional regulation of anti-inflammatory and immunosuppressive genes. It also activates the mineralocorticoid receptor (MR) with lower affinity, contributing to electrolyte and fluid balance effects.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist and antiemetic; dextromethorphan is a non-opioid antitussive that acts as an NMDA receptor antagonist and sigma-1 receptor agonist.
10-20 mg orally every 8 hours as needed for nasal congestion.
5 mL (containing promethazine 6.25 mg and dextromethorphan 15 mg) orally every 4-6 hours as needed, not to exceed 30 mL (promethazine 37.5 mg, dextromethorphan 90 mg) per 24 hours.
None Documented
None Documented
8-12 hours (terminal); clinical context: requires dosing every 12 hours; reduced clearance in elderly and renal impairment
Promethazine: 9-16 h; dextromethorphan: 3-5 h (extensive metabolizers), 30-50 h (poor metabolizers). Clinical context: dosing interval typically 4-6 h for dextromethorphan; promethazine accumulates with repeated dosing.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Renal: promethazine ~6% unchanged, dextromethorphan ~0.5% unchanged; metabolites primarily renal. Biliary/fecal: minor routes for both.
Category C
Category A/B
Antihistamine/Decongestant
Antihistamine / Antiemetic